DOI: 10.1200/jco.24.00248 ISSN: 0732-183X

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Harold J. Burstein, Angela DeMichele, Lesley Fallowfield, Mark R. Somerfield, N. Lynn Henry, N. Lynn Henry, Zoneddy Dayao, Anthony Elias, Kevin Kalinsky, Lisa M. McShane, Beverly Moy, Ben Ho Park, Kelly M. Shanahan, Priyanka Sharma, Rebecca Shatsky, Erica Stringer-Reasor, Melinda Telli, Nicholas C. Turner, Angela DeMichele, Harold J. Burstein, Debra L. Barton, Ali Dorris, Lesley J. Fallowfield, Dharamvir Jain, Stephen R.D. Johnston, Larissa A. Korde, Jennifer K. Litton, Erin R. Macrae, Lindsay L. Peterson, Praveen Vikas, Rachel L. Yung, Hope S. Rugo,
  • Cancer Research
  • Oncology

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only).

More from our Archive